U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036978) titled 'Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer' on June 12.
Brief Summary: Brief Summary
The goal of this observational study is to identify biomarkers and develop a personalised treatment stratification model for patients with unresectable pancreatic ductal adenocarcinoma (PDAC) in Taiwan. The main questions it aims to answer are:
* What serum metabolomic profiles predict treatment response and patient survival?
* How do immune response markers and gut microbiome composition correlate with therapeutic outcomes?
* Can a combined multi-omic stratification algorithm enhance personalised therapy plan...